-
The Importance of Follow-up Screening
Terri Ann DiJulio, a long-time lung cancer survivor who has overcome three lung cancer diagnoses, talks about the importance of follow-up screenings for lung cancer, family history considerations, and...
IN THE SPOTLIGHT
-
HOPE Summit
Make friends and get savvy about life with lung cancer! Each year, LUNGevity Foundation brings together patients and caregivers to build friendships and learn from reliable experts... -
Finding Clinical Trials for Lung Cancer: Tools and Resources
Clinical trials are an important option for patients because the newest treatment approaches, not available otherwise, are being tested in them. Clinical trial research leads to... -
Fuel for the Future: Good Nutrition for the Lung Cancer Community
Learn valuable information about good nutrition that can help you live well through lung cancer treatment and beyond. Gain insight and tips from Oncology Dietitian Lori Bumbaco, MS... -
Researchers Make New Inroads for EGFR Exon20+ NSCLC Patients
While our bodies can have a wide range of naturally occurring, harmless mutations in different genes, some mutations, called driver mutations, are key to driving the development of... -
The Benefits of Palliative Care for People Living with Lung Cancer
Palliative care is supportive care that anticipates, prevents, and treats the symptoms and side effects of the disease and its treatment. It is intended to improve one's quality of... -
Shared Decision-Making, Self-Advocacy, and Dealing with Financial Toxicity
Cardinale Smith, MD, PhD, oncologist and associate professor at the Icahn School of Medicine at Mt. Sinai, explains how shared decision-making with one's healthcare team can create... -
The Healing Power of Stress, with Mike Verano
Mike Verano is a cancer survivor, author, and counselor with over 28 years of experience in the mental health field. Mike joins LUNGevity's Angela James to share concepts from his... -
Healing is an Art, with Genevieve De Renne
Genevieve De Renne is a caregiver and artist whose artwork has been featured on the cover of three recent issues of the Journal of Oncology Navigation & Survivorship. Genevieve... -
Pneumonitis: A Common Side Effect
In this video, nurse practitioner Lauren Welch, MSN, NP-C, AOCNP, from the Sarah Cannon Research Institute at Tennessee Oncology offers a quick review of pneumonitis - a common... -
Thriving with Cancer, with Dann Wonser
Dann Wonser, a 16-year lung cancer survivor and author of the book Second Wind – Thriving with Cancer, joins LUNGevity's Angela James to share learnings from his cancer journey and...
RET, MET, and EGFR: An unusual tale of three oncogenes in lung cancer
RET, MET, and EGFR: An unusual tale of three oncogenes in lung cancer
LUNGevity's Upal Basu Roy, PhD, MPH, Executive Director, Research, discusses innovative research into RET+ NSCLC with patient advocates and the scientist conducting the studies. Panelists include Omaima Salous (diagnosed with RET+ NSCLC and co-founder of The Hamoui Foundation), Dr. Hilary Hammell (diagnosed with RET+ NSCLC and co-chair of RETpositive), and Dr. Tejas Patil (Assistant Professor, University of Colorado). The discussion focuses on Dr. Patil’s RET+ NSCLC research project and why…
Real-World Drug Development at the Targeted Therapies of Lung Cancer Meeting
Real-World Drug Development at the Targeted Therapies of Lung Cancer Meeting
The development of new treatments for any disease relies on the collaborative efforts of many different stakeholders, such as scientists, clinicians, patient advocacy groups, regulators, and pharmaceutical and biotech companies.
During scientific conferences that happen throughout the year, stakeholders cobble together opportunities to discuss the current state of treatments and strategize ways to bring emerging lifesaving treatments to patients.
Each year, there is one key conference…
Researchers Make New Inroads for EGFR Exon20+ NSCLC Patients
Researchers Make New Inroads for EGFR Exon20+ NSCLC Patients
While our bodies can have a wide range of naturally occurring, harmless mutations in different genes, some mutations, called driver mutations, are key to driving the development of cancer. There are many driver mutations. Researchers have been developing drugs that target specific driver mutations in lung cancer, creating therapies for those patients whose lung cancer harbors them.
Early Targeting of EGFR
In the early 2000s, EGFR was the first gene in non-small cell lung cancer (NSCLC) to be…
Targeted Therapy Options for Patients with EGFR Exon20+ NSCLC
Targeted Therapy Options for Patients with EGFR Exon20+ NSCLC
Researchers have made tremendous progress in treating lung cancer by identifying key mutations in genes that drive the growth of lung cancer. Once these “driver” mutations are identified, researchers can work to target these mutations with specific treatments, called targeted therapies.
FDA-approved targeted therapies exist for treating EGFR-positive NSCLC, or non-small cell lung cancer (NSCLC) patients whose tumors test positive for exon19 and exon21 L858R mutations in the EGFR (epidermal…
Science Spotlight: NSCLC Transformation into SCLC
Science Spotlight: NSCLC Transformation into SCLC
Take a behind-the-scenes look at how researchers study lung cancer. Join lung cancer researcher Triparna Sen, PhD, as she digs into what’s known about how EGFR-positive NSCLC cells transform into SCLC to escape targeted therapy treatment. SCLC transformation is a common resistance mechanism for multiple types of NSCLC, including EGFR, ALK, and RET.
This Facebook Live event is hosted by Amy Moore, PhD, LUNGevity’s Vice President of Global Engagements and Patient Partnerships. Dr. Sen is Co-…
Key Findings from ASCO 2022
Key Findings from ASCO 2022
Upal Basu Roy, PhD, MPH, LUNGevity's Executive Director of Research, speaks with Charles Rudin, MD, PhD, about the key findings from the recent meeting of the American Society for Clinical Oncology (ASCO) and what they mean for the lung cancer community.
We're Live-Tweeting from ASCO June 3-7!
We're Live-Tweeting from ASCO June 3-7!
LUNGevity’s Dr. Upal Basu Roy and Dr. Amy Moore will be live-tweeting from the American Society of Clinical Oncology (ASCO) annual meeting. Follow LUNGevity on Twitter and the hashtags #ASCO22 and #LCSM to be a part of the action. Times and topics of live-tweeted sessions are as follows:
Fri, Jun 3, 2022 | 2:00 PM – 5:00 PM EDT | Lung Cancer—Non-Small Cell Metastatic
Sun, Jun 5, 2022 | 9:00 AM – 10:15 AM EDT | Treatment Sequencing in Resectable Lung Cancer…
Lung Cancer Treatment Landscape: New Options and Ongoing Challenges
Lung Cancer Treatment Landscape: New Options and Ongoing Challenges
Drs. Upal Basu Roy, Amy Moore, and Dhru Deb discuss their recent publication in which they presented an analysis of the lung cancer drug pipeline. They talk about what it means for patients, new drugs under development for NSCLC and SCLC, and some of the ongoing challenges and opportunities this rapid growth means for the lung cancer community.
New Options in Adjuvant Therapy for Early-Stage NSCLC
New Options in Adjuvant Therapy for Early-Stage NSCLC
Historically, surgery has been the most effective treatment for patients with early-stage non-small cell lung cancer (NSCLC). While technological improvements, such as the development of minimally invasive techniques (such as video-assisted thoracoscopic surgery or VATS), have made surgeries safer for patients, the ability to cure early-stage NSCLC patients hasn’t improved significantly in recent decades. Even after successful surgeries that completely remove the visible tumor, about half of…
Studying Drug Resistance From a New Angle
Studying Drug Resistance From a New Angle
The development of “targeted therapies” which block the function of mutant proteins within tumor cells has revolutionized the treatment landscape for many cancers, most of all lung cancer. EGFR is one such protein which is often altered (mutated) in lung cancers. Over the past decade, multiple EGFR targeted therapies have been developed, with each generation of drugs becoming increasingly potent.
At present, patients with advanced EGFR-mutated lung cancer are treated with osimertinib (Tagrisso…
Highlights of the 2022 AACR meeting
Highlights of the 2022 AACR meeting
The American Association for Cancer Research (AACR) 2022 meeting was held in New Orleans from April 9 to 13. Doctors and researchers worldwide joined together virtually and in person to make this year’s meeting one of the largest gatherings since the start of the pandemic. They shared the many exciting developments in cancer research and treatment that emerged over the last year. This year’s meeting is another testament to “Science doesn’t stop, and scientists never sleep!” Here, we discuss…